Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com  x.com 

Aehr Test Systems has become a key picks-and-shovels supplier to the AI chip boom, with its Sonoma platform the go-to system for reliability testing of high-power AI processors. On April 16, 2026, it announced a $41M follow-on order, its largest ever, from an unnamed hyperscale AI chip leader for custom AI ASIC testing, with revenue from fiscal 2027. Backlog doubled to $38.7M, second-half FY26 bookings exceed $92M, and FY26 should hit the high end of $45-50M guidance. x.com 

Aehr Test Systems' addressable market looks tiny compared with 200 other AI companies, making it unattractive. x.com 

Aehr Test Systems' AI wafer-level burn-in business is scaling, with a $22M follow-on order from its lead AI processor customer to expand capacity for high-volume production. That customer is already planning more capacity, and Aehr is expanding talks with other hyperscalers. The stock reached fresh all-time highs, and its recent strength looks like institutional accumulation. x.com  x.com  x.com 

Aehr Test Systems' lead hyperscale customer is expanding production with about $6M of follow-on Sonoma orders for a second-generation AI processor. These are production-capacity orders, not evaluations, and the customer expects the second processor eventually to exceed the volumes of the first, already in high-volume production. Teradyne's new burn-in on Titan HP overlaps only with package-level Sonoma work, not FOX-XP wafer-level burn-in that screens dies before costly CoWoS packaging. x.com 

Aehr Test Systems is key to AI manufacturing and can even be a bottleneck, but at almost 20x revenue through 2028 at the current price, it is stratospherically priced. The risk is giant if something goes wrong for the company or for the AI ramp, and even a slowdown could be deadly at such high valuations. Tech moats are not the same as financial moats. x.com 

Aehr Test Systems stands to benefit from Broadcom's custom AI chip ramp because these 600W–2kW multi-die packages need burn-in testing. Broadcom said XPU shipments rose 3.5x and laid out $115B of AI revenue in FY27 and $230B in FY28 with supply secured, backed by multi-gigawatt Google, Anthropic, OpenAI and Meta deployments. Aehr won a record $41M package-level burn-in order from its lead hyperscale customer for a custom AI ASIC, with a next-gen device moving to production later this year. x.com 

Aehr Test Systems' thesis strengthened with its best report ever, though the stock's risk/reward is now impaired. The most important disclosure was that its lead AI customer has eliminated system-level burn-in and moved production entirely to Aehr's wafer-level systems. FY27 guidance of $130-150M far exceeded the $85M consensus. x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr's AI burn-in growth case is intact, but confidence in its competitive edge may need to come down as Teradyne moves into high-power burn-in. Teradyne's Titan HP, already in production, combines system-level test and burn-in and could absorb spending on dedicated tools, pressuring Sonoma orders and pricing. Aehr still won about $6M of follow-on Sonoma orders for a hyperscaler's second AI chip, with no sign FOX-XP is replaced. If the market expands enough, revenue can grow as share falls. … Show more